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Basic mechanisms in gene expression are currently being investigated as
targets in cancer therapeutics. One such fundamental process is the addition
of the cap to pre-mRNA, which recruits mediators of mRNA processing and
translation initiation. Maturation of the cap involves mRNA cap guanosine
N-7 methylation, catalysed by RNMT (RNA guanine-7 methyltransferase).
In a panel of breast cancer cell lines, we investigated whether all are equiva-
lently dependent on RNMT for proliferation. When cellular RNMT activity
was experimentally reduced by 50%, the proliferation rate of non-
transformed mammary epithelial cells was unchanged, whereas a subset of
breast cancer cell lines exhibited reduced proliferation and increased apopto-
sis. Most of the cell lines which exhibited enhanced dependency on RNMT
harboured oncogenicmutations in PIK3CA,which encodes the p110a subunit
of PI3Ka. Conversely, all cell lines insensitive to RNMT depletion expressed
wild-type PIK3CA. Expression of oncogenic PIK3CAmutants, which increase
PI3K p110a activity, was sufficient to increase dependency on RNMT. Con-
versely, inhibition of PI3Ka reversed dependency on RNMT, suggesting
that PI3Ka signalling is required. Collectively, these findings provide evi-
dence to support RNMT as a therapeutic target in breast cancer and suggest
that therapies targeting RNMT would be most valuable in a PIK3CA
mutant background.1. Background
Basic mechanisms in gene expression are currently being investigated as targets
in cancer therapeutics [1,2]. In eukaryotes, gene expression is dependent on the
mRNA cap, a structure that protects nascent transcripts from nucleases and
recruits complexes which mediate mRNA processing, including splicing,
export and translation initiation [3–5]. The mRNA cap forms during transcrip-
tion and remains on the transcript throughout its lifetime. The basic cap
structure is m7G(50)ppp(50)Xm (X denotes the first transcribed nucleotide),
7-methylguanosine linked to the first transcribed nucleotide via 50 to 50 tripho-
sphate bridge. A series of enzymes catalyse cap formation initiating with
RNGTT (RNA guanylyltransferase and 50 phosphatase), which catalyses the
addition of the inverted guanosine cap to the nascent transcript. Subsequently,
RNMT (RNA guanine-7 methyltransferase) and its activating subunit, RAM
(RNMT-activating miniprotein), are recruited to transcribing RNA pol II
[6–8]. RNMT–RAM methylates the guanosine cap on the N-7 position to
create the cap structure, m7G(50)ppp(50)X [9,10]. RNMT–RAM also has a
major role in enhancing the transcription of the most active genes via
interactions with protein complexes of the transcription machinery [11].
RNMT–RAM can also be involved in the process of recapping, during which
partially capped or uncapped transcripts receive a cap in the cytoplasm [12].
royalsocietypublishing.org/journal/rsob
Open
Biol.9:190052
2Thus, RNMT–RAM has a potent role in gene expression,
promoting transcription and translation.
Cellular signalling pathways can regulate mRNA cap
formation on specific target mRNAs, resulting in the
regulation of their expression. For example, c-Myc and E2F1
(and potentially other transcription factors) increase RNA
pol II phosphorylation which promotes mRNA cap formation
via recruitment of the capping enzymes [13–17]. c-Myc-
dependent mRNA cap methylation also requires upregulation
of SAHH, the enzyme which hydrolyses the inhibitory bi-
product of methylation reactions [18]. Upregulation of
mRNA cap formation is critical for c-Myc function; inhibition
of this process is synthetic lethal with deregulated c-Myc
[15,18]. Formation of the mRNA cap is also regulated during
the cell cycle by CDK1-dependent phosphorylation and acti-
vation of RNMT [19]. As CDK1 and c-Myc are implicated in
tumorigenic events and cap-dependent mRNA translation is
deregulated in many cancers, this raises the potential of utiliz-
ing the mRNA capping enzymes as therapeutic targets to
selectively inhibit protein synthesis in cancer cells [20,21]. In
particular, because RNMT ligands have low polarity, there
may be an opportunity to create active site inhibitors with a
low charge that are able to cross the plasma membrane [22].
When considering RNMT as a therapeutic target, is it valu-
able to determine which oncogenes drive a heightened state of
dependency on RNMT. This gives an important indication of
which cancer types and patient populations are most likely
to response to RNMT inhibitors. In this study, we investigated
the impact of RNMT depletion on the proliferation of a panel
of breast cancer cell lines. We found that cells with activating
mutations in PIK3CA, which are present in around 35% of
breast cancers, exhibit enhanced dependency on RNMT for
proliferation [23]. Cells expressing wild-type (WT) PIK3CA
had their dependency on RNMT increased by the exogenous
expression of oncogenic PIK3CA mutants, which increase
PI3Ka activity. Conversely, cells expressing oncogenic
PIK3CA mutations had their enhanced RNMT dependency
reversed by the use of low doses of PI3Ka inhibitors,
suggesting that PI3Ka signalling is mediating this
dependency. Taken together, these data demonstrate that
breast cancer cells with activating mutations in PIK3CA are
selectively sensitive to RNMT inhibition.2. Material and methods
2.1. Tissue culture
Cells were cultured at 378C and 5% CO2. The carcinoma cells
were purchased from the American Type Culture Collection
(ATCC) and IMECs (immortalized normal mammary epi-
thelial cell lines) kindly provided by Dr James DiRenzo
(Dartmouth Medical School). Experiments were typically
performed within four weeks of culture. Breast carcinoma
cell lines were maintained in RPMI, 10% FBS, 2 mM
L-glutamine and 1% Anti-anti. IMEC cells were maintained
in DMEM/F12, 2 mM L-glutamine, 5 mg ml21 insulin,
10 ng ml21 EGF, 0.5 mg ml21 hydrocortisone and 1% Anti-
anti. pBMN-IRES neo-constructs containing Myc-PIK3CA,
RNMT-GFP and mutants or empty vector control were trans-
duced into cells by retro-viral infection and selected using
0.5 mg ml21 G418 for 7 days.2.2. PIK3CA sequencing
RNA was extracted using the GeneJET RNA Purification Kit
(ThermoFisher Scientific). Approximately 5–10 mg of RNA
was digested with 2 ml of Turbo DNAse (ThermoFisher
Scientific) to remove genomic DNA and purified using the
RNA Clean & Concentrator Kit (Zymo Research), and 1 mg
of RNA was used in the reverse transcription reaction using
RevertAid H Minus Reverse Transcriptase (ThermoFisher Scien-
tific) and the following RT primer: tcaaaccctgtttgcgttta. About
2 ml of reverse transcription reaction was used as a template in
the PCR with KOD Hot Start DNA Polymerase (Merck)
with primers PIK3CA_fwd2 tgctttgggacaaccataca and
PIK3CA_rev3 cctatgcaatcggtctttgc. The PCR product was
purified with the QIAquick PCR Purification Kit (Qiagen)
and sequenced using the following primers: PIK3CA_
FWD2 tgctttgggacaaccataca; 669R cacagtcatggttgattttcaga;
1166R cctgggattggaacaaggta; 1288F ggcatggggaaatataaacttg;
1664R tctcctgctcagtgatttcaga; 2143R gcctcgacttgcctattcag;
2312F caggcttgaagagtgtcgaa; 2636R gaactgcagtgcacctttca;
PIK3CA_REV3 cctatgcaatcggtctttgc.
2.3. Cell transfection, treatment and counting
Cells were seeded at equivalent density, at approximately
2.5  105 cells per six-well plate, and immediately transfected
with siRNAs (Dharmacon) using Lipofectamine RNAiMax
transfection reagent. For a six-well dish, 0.16 nmol siRNA
was transfected with 3 ml of Lipofectamine RNAiMax and
200 ml of serum-free DMEM. siRNAs used were siRNMT 1
(D-019525-01-0050), siRNMT 2 (019525-02-0050), siRNMT 3
(019525-03-0050) and non-targeting control (D001210-03-
0050). When relevant, cells were treated with 0.1 mM
staurosporine for 3 h prior to lysis and 50 nM GDC-0941 or
15 nM BYL719 for 72 h prior to lysis or cell counting. For
experiments requiring longer than 48 h siRNA transfection,
the growth media were replenished at 48 h. Cells were
counted using a Countess cell counter (Life Technologies).
2.4. Generation of GFP-RNMT and PIK3CA mutant stable
cell lines
HCC-1806 cells were retrovirally transduced to stably express
siRNA-resistant, GFP-tagged full-length RNMT. ZR-751,
IMEC and MDA-MB-231 cells were retrovirally transduced
to stably express Myc-tagged oncogenic mutants of p110a
(E545K, C420R and H1047R).
2.5. Statistical analysis
Statistical significance was assessed by one-way analysis
(ANOVA) followed by Dunnett’s multiple comparison tests
using GraphPad PRISM 5.0. A value of p  0.05 is denoted
with *, p  0.01 denoted with **, p  0.001 denoted with ***.
2.6. Cell extract preparation
Cell lysis was performed at 48C. Culture media were
removed, cells were washed twice with ice-cold PBS and
lysed in ice-cold F buffer, comprising 10 mM Tris (pH
7.05), 50 mM NaCl, 30 mM Na-pyrophosphate, 50 mM NaF,
5 mM ZnCl2, 10% glycerol, 0.5% Triton X-100, 1 mM EGTA,
royalsocietypublishing.org/journal/rsob
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31 mM EDTA, and 1 mM sodium orthovanadate) sup-
plemented with 0.1 TIU (trypsin inhibitor unit) aprotinin,
1 mM pepstatin, 10 mM leupeptin and 1 mM DTT immedi-
ately before use. For analysis of phosphorylated protein,
lysis buffer was supplemented with Sigma Phosphatase
Inhibitors (cocktail mixtures 2 þ 3). Cell lysates were col-
lected by scraping and the soluble fraction was collected
following centrifugation at 16 000 g for 10 min at 48C. Protein
concentration was determined using the Bradford method
and extracts were normalized for protein content. Typically,
5–20 mg of cell extract was analysed. Band intensity was
quantitated using Image J software.
2.7. Antibodies
Anti-RNMT, RAM and AKT antibodies were developed
in-house and raised against full-length recombinant human
proteins in sheep and sera purified against the antigen.
Other antibodies purchased were Actin (Abcam-8226),
PARP (CST 9541), AKT T308P (CST 9275), AKT S473P (CST
9271), 4E-BP1 Thr 37/46 (CST 9459), P-4EBP Thr 70 (CST
9455), 4E-BP (CST 9452), p70 S6 kinase Thr 389 (CST 9205),
c-Myc (CST 9402) and p70 S6 kinase (CST 9202).
2.8. In vitro cap methyltransferase assay
0.25, 0.5 or 1 mg of cell extracts were incubated with 2 mM
SAM, 20 U RNasin, MT buffer (10 mM Tris pH 8, 0.6 mM
KCl, 0.125 mM MgCl2) and in vitro transcribed
32P
G-capped RNA at 378C for 10 min. RNA was purified
and resuspended in 4 ml of 50 mM Na-acetate (pH 5.5).
RNA was P1 nuclease-treated to release free guanosine
cap. GpppG (basic guanosine cap) and m7GpppG
(N7-methylated guanosine cap) resolved on PEI cellulose plates
in 0.4 M ammonium sulfate, visualized by phosphoimager and
quantified using AIDA IMAGER software.3. Results
3.1. Breast cancer cell lines harbouring oncogenic
PIK3CA exhibit enhanced dependency on RNMT
We investigated the proliferative response of a panel of breast
cancer cell lines and a normal mammary epithelial cell line to
a reduction in RNMT expression. Initially, a panel of eight
breast cancer cell lines with a spectrum of mutations was
analysed: MCF7, HCC1806, JIMT-1, T47D, BT-549, MDA-MB-
231, CAMA-1 and ZR-75-1 (table 1). Cell lines were purchased
from ATCC (American Type Culture Collection) and used
within four to sixweeks of culture to reduce passage-dependent
effects. Known mutations of cancer-associated genes in these
cell lines were extracted from the COSMIC database (table 1).
In addition, a low-passage, non-transformed TERT-IMEC
(TERT-immortalized mammary epithelial cell line) was ana-
lysed [24]. RNMT expression was reduced by transfection of
three independent RNMT siRNAs and a non-targeting siRNA
control. All cell lines harbouring PIK3CA-activating mutations
(MCF7, JIMT-1 and T47D, marked with a red asterisk), and
one cell line expressing WT PIK3CA (HCC-1806), exhibited
reduced proliferation in response to transfection of all three
RNMT siRNAs (figure 1a). By contrast, the proliferation of
IMECs and other breast cancer cell lines expressing WTPIK3CA (BT-549, MDA-MB-231, CAMA-1 and ZR-75-1) was
unaffected by RNMT siRNA transfection. The PIK3CA coding
region sequence was verified for all cell lines (electronic sup-
plementary material, figure S1). Combining three independent
experiments, the average cell number 96 h after RNMT siRNA
1 transfectionwas calculated relative to the cell number in a con-
trol transfection (figure 1b). In agreement with the growth
curves in figure 1a, in response to RNMT siRNA transfection,
there was a significant reduction in the cell number for MCF7,
HCC-1806, JIMT-1 and T47D cell lines compared with IMEC.
However, BT-549, CAMA-1, ZR-75-1 and MDA-MB-231 cell
lines did not exhibit a significant loss in cell number following
RNMT siRNA transfection. This difference in sensitivity to
RNMT siRNA transfection did not correlate with the level of
RNMT reduction. All cell lines exhibited an equivalent
reduction in RNMT expression in response to transfection of
all three RNMT siRNAs (figure 1c). As observed previously,
expression of the RNMT-activating subunit, RAM, was also
reduced in response to reduced RNMT expression (figure 1c)
[10,25]. RNMTandRAMare co-translated, and their interaction
protects the two proteins from proteasome-mediated
degradation.
Since we observed a similar proliferative defect following
transfection of three independent RNMT siRNAs, it is likely
that this impact is specifically due to a reduction in RNMT
levels. To strengthen this conclusion, an RNMT-GFP con-
struct resistant to RNMT siRNA 1 was introduced into
HCC1806 cells by retroviral infection. As expected, transfec-
tion of RNMT siRNA 1 inhibited endogenous RNMT
expression but did not inhibit expression of RNMT-GFP
(figure 2a). Consistent with figure 1, depletion of endogenous
RNMT significantly inhibited the proliferation of control
HCC1806 cells, but this effect was reversed by the expression
of RNMT-GFP (figure 2b). This confirms that the proliferative
defect observed following RNMT siRNA transfection is
probably due to a reduction in RNMT expression and not a
consequence of siRNA off-target effects
The reduction in cell number that we observed in
response to reduced RNMT expression could be due, in
part, to an increase in apoptosis. Inhibition of RNMT and
RAM has been observed to induce apoptosis in HeLa cells,
a cervical cancer cell line [10,26]. We analysed apoptosis in
a subset of our breast cancer cell panel by detecting fragments
of PARP, a nuclear antigen cleaved during apoptosis
(figure 2c). All four cell lines investigated were competent
to undergo apoptosis; all exhibited cleaved PARP in response
to incubation with Staurosporine, a pro-apoptotic agent. Cell
lines exhibiting enhanced dependency on RNMT (MCF7 and
HCC-1806), also exhibited PARP cleavage in response to
reduced RNMT expression, indicating that apoptosis was
taking place. MDA-MB-231 and ZR-75-1 cells, which do not
exhibit a proliferative defect in response to RNMT siRNA
transfection, also did not exhibit PARP cleavage in response
to reduced RNMT expression (figure 2c). These data demon-
strate that RNMT depletion induces a cytotoxic response in
RNMT-dependent breast cancer cell lines.3.2. RNMT dependency does not correlate with RNMT
expression, activity or rate of protein synthesis
To investigate the molecular mechanisms governing depen-
dency on RNMT, we investigated whether cells sensitive to
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Figure 1. Breast cancer cell lines expressing PIK3CA mutants are sensitive to RNMT depletion. Breast cancer cell lines MCF7, HCC1806, JIMT-1, T47D, BT-549, MDA-
MB-231, CAMA-1 and ZR-75-1, and a normal mammary epithelial cell line, IMEC, were transfected with three independent RNMT siRNAs or a non-targeting control
siRNA. (a) Over 4 days, average cell number and standard deviation from three independent transfections are reported. (b) Ninety-six hours following transfection
with RNMT siRNA1, the cell number was determined relative to cells transfected with non-targeting siRNA. Average result and standard deviation for three inde-
pendent experiments are reported. Statistical significance was assessed by ANOVA followed by Dunnett’s multiple comparison tests. ‘***’ indicates a p-value of less
than 0.001 compared with IMEC control. (c) Seventy-two hours post-transfection, expression of RNMT, RAM and actin was detected by western blot. Data presented
are one out of two independent experiments with consistent results. Cells expressing oncogenic PIK3CA mutants are indicated with red asterisks.
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6RNMT siRNA transfection (MCF7, HCC-1806, JIMT-1 and
T47D) exhibited differences in RNMT expression and protein
synthesis compared with those which are insensitive (IMEC,
BT-549, MDA-MB-231, CAMA-1 and ZR-75-1) (figure 3). In
all figures, the breast cancer cell lines are presented in order
of sensitivity to RNMT reduction, MCF7 being the most sen-
sitive and ZR-75-1 being the least sensitive. IMECs were
analysed as a control cell line.
We investigated whether cellular dependency on RNMT
correlated with RNMT expression or activity, measuringboth basal levels and levels following RNMT siRNA trans-
fection. RNMT and RAM expression were analysed by
western blot performed on four independent samples
(figure 3a,b). Expression of RNMT and RAM varied little
across the cell panel, and a correlation between RNMT and
RAM expression and dependency on RNMT was not
observed. Cellular N7 cap guanosine methyltransferase
activity, which is dependent on RNMT expression, also
did not correlate with dependency on RNMT (figure 3c,d )
[27]. For each cell line, the mRNA cap methyltransferase
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Figure 2. RNMT dependency correlates with increased apoptosis in breast cancer cell lines. (a) HCC1806 cells expressing siRNA-resistant RNMT-GFP or GFP control
were transfected with RNMT siRNA1 or non-targeting siRNA. After 72 h, the resultant expression of RNMT-GFP, RNMT, RAM and actin was analysed by western blot.
(b) Cell number relative to GFP-expressing control cells was determined, and statistical significance was calculated as above. (c) The cell lines indicated were trans-
fected with three independent RNMT siRNAs. After 96 h, RNMT, PARP, cleaved PARP (cl PARP) and actin were detected by western blot. Cells were treated with
staurosporine (St) to generate a positive control for PARP cleavage. Cells expressing oncogenic PIK3CA mutants are indicated with a red asterisk.
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7activity assay was performed on titration of cell extracts to
determine the linear range of the assay (electronic
supplementary material, figure S2). In this assay, a guanosine-
capped transcript was incubated with cell extracts and the
methyl donor, SAM (S-adenosyl methionine). Following
incubation, the proportion of transcripts with an N7 methyl-
guanosine cap (m7G(50)ppp(50)X) was determined by thin
layer chromatography. Across the cell panel, only two cell
lines exhibited significantly different N7 cap guanosine
methyltransferase activity compared with IMEC; however,
one was a cell line sensitive to RNMT siRNA transfection
(HCC-1806), and the other was insensitive (CAMA-1)
(figure 3c). Furthermore, the reduction in N7 cap guanosine
methyltransferase activity following RNMT siRNA transfec-
tion did not vary significantly across the cell panel
(figure 3d ). All cell lines exhibited a 40–60% reduction in
N7 cap guanosine methyltransferase activity in response to
RNMT siRNA transfection, consistent with RNMT being
equivalently depleted (figure 1c).
Given that RNMT–RAM expression is required for effi-
cient cap-dependent translation, a reasonable hypothesis
was that cells with higher protein synthesis or proliferation
rates are more sensitive to loss of RNMT. An approximation
of the protein synthesis rate was determined by measuring
the rate of radio-labelled amino acid incorporation into
cellular proteins. Although HCC1806, JIMT-1, CAMA-1 and
ZR-75-1 cells exhibited higher basal net protein synthesis
rates than IMEC, this did not correlate with dependency on
RNMT (figure 3e). The reduction in protein synthesis in
response to RNMT siRNA transfection also did not vary sig-
nificantly across the cell panel (figure 3f ). Furthermore, basalcell doubling time did not correlate with sensitivity to a
reduction in RNMT (figure 3g).
3.3. RNMT dependency is induced by expression of
oncogenic PIK3CA mutants
Three of the breast cancer cell lines sensitive to a reduction in
RNMT have oncogenic hotspot activating PIK3CA mutations;
MCF7 expresses PIK3CA E545 K, T47D expresses PIK3CA
H1047R, and JIMT-1 expresses PIK3CA C420R (table 1; elec-
tronic supplementary material, figure S1). Conversely, all of
the cell lines insensitive to RNMT inhibition expressed
PIK3CA WT. No other cancer-associated mutations in the
cell panel correlated with sensitivity to RNMT depletion.
PIK3CA encodes the p110a subunit of the heterodimeric
lipid kinase, PI3 K, which, upon stimulation by growth fac-
tors, activates downstream kinases including AKT and
PDK1 (table 1). These effector kinases regulate major pro-
cesses, including cell proliferation, growth and survival
[28,29]. PIK3CA mutations are found in approximately 35%
of breast cancer patients, with C420R, E545K and H1047R
being the most common variants [23,30,31]. No other
cancer-associated mutations in the cell panel correlated
with sensitivity to RNMT depletion. Oncogenic PIK3CA
mutants can confer growth advantage and render cells exqui-
sitely sensitive to inhibition of PI3Ka [32–34]. Indeed, MCF7,
T47D and JIMT-1 cell lines were found to have the highest
sensitivity to the PI3Ka inhibitor, BYL719, in the breast
cancer cell line panel, demonstrating that these cell lines
require PI3Ka for proliferation and survival [35] (electronic
supplementary material, figure S3).
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Figure 3. RNMT dependency does not correlate with RNMT expression or activity, the rate of protein synthesis or the rate of cell proliferation. (a) Levels of RNMT and
RAM in log-phase cell extracts were analysed by western blot. Blots presented are representative of four independent experiments. (b) RNMT and RAM band
intensities were quantified using IMAGEJ software. The bar charts depict average band intensity and standard deviation for four independent experiments.
(c) N7 guanosine cap methyltransferase activity was determined in cell extracts using an in vitro assay. The chart depicts the average cap methyltransferase activity
and standard deviation for four independent experiments. (d ) N7 guanosine cap methyltransferase activity was determined in cell extracts 48 h after transfection
with RNMT siRNA1 and expressed relative to values in control cells. (e) The rate of 35S methionine and 35S cysteine incorporation into cellular proteins was deter-
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by Dunnett’s multiple comparison tests in comparison with IMEC values: *p  0.05; **p  0.01; ***p  0.001. Cells expressing oncogenic PIK3CA mutants are
indicated with red asterisks.
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8To determine whether oncogenic PIK3CA mutations sen-
sitize cells to loss of RNMT, Myc-tagged PIK3CAWT, C420R,
E545K, H1047R and vector control were introduced into
ZR-75-1 cells by retroviral infection. ZR-75-1 cells expressedWT PIK3CA and were demonstrated previously to be insen-
sitive to RNMT siRNA transfection (figures 1 and 2). The
expression of PI3 K p110a WT (product of PIK3CA gene)
and mutants was confirmed in ZR-75-1 cells by the detection
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Figure 4. Expression of oncogenic PI3K p110a mutants C420R, E545K and H1047R increases RNMT dependency in ZR-75-1 cells. (a) Myc-tagged PI3K p110a WT
and mutants (C420R, E545 K and H1047R) were expressed in ZR-75-1 cells and detected by 9E10 antibody (anti-Myc tag) in western blots. (b) AKT Thr 308 and Ser
473 phosphorylation was analysed by western blot in the same cell extracts. (c) ZR-75-1/PI3K p110a cell lines were transfected with RNMT siRNA1 or non-targeting
control for 48 h. Western blots were performed to detect RNMT. (d ) Following transfection with siRNA, the cell number was determined over 3 days. Average cell
number and standard deviation from three independent transfections are reported. (e) Seventy-two hours after transfection with RNMT siRNA 1 and 2, the cell
number was determined relative to cells transfected with non-targeting siRNA. The average result and standard deviation for three independent experiments are
depicted. The statistical significance was assessed by ANOVA followed by Dunnett’s multiple comparison tests. ‘***’ indicates a p-value of less than 0.001 compared
with cells transfected with control siRNA.
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9of p110a (figure 4a). The activity of oncogenic p110amutants
was confirmed by the detection of increased AKT Thr 308
and Ser 473 phosphorylation, an established downstream
output of PI3K signalling (figure 4b). As expected, ZR-75-1
cells expressing oncogenic PIK3CA mutants exhibited
increased sensitivity to the p110a inhibitor, BYL719 [36] (elec-
tronic supplementary material, figure S4). Expression of
RNMT was reduced in the ZR-75-1 cell lines by siRNA trans-
fection (figure 4c). Basal RNMT expression and knockdown
efficiency were equivalent in all cell lines. The proliferation
rate of ZR-75-1 cells did not alter in response to exogenousexpression of PIK3CA WT or mutants (figure 4d ). However,
expression of the PIK3CA mutants increased the sensitivity
of ZR-75-1 cells to reduced RNMT expression (figure 4d,
lower chart). In electronic supplemental material, figure S5,
data from both charts from figure 4d are presented in the
same chart to illustrate that expression of PIK3CA mutants
does not significantly alter the proliferation rate. Further-
more, RNMT siRNA transfection does not alter the
proliferation rate in cells expressing PIK3CA WT, but does
reduce the proliferation rate in cells expressing PIK3CA onco-
genic mutants. Transfection of two independent RNMT
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10siRNAs caused a significant decrease in cell number in cells
expressing oncogenic PIK3CA mutants (figure 4e).
To determine whether the expression of oncogenic
PIK3CA mutants increases RNMT dependency in additional
cell lines, PIK3CA WT, C420R, E545K, H1047R and vector
control were expressed in the non-transformed mammary
epithelial cell line IMEC and the breast cancer cell line
MDA-MB-231 (figure 5a,e). Both cell lines expressed WTPIK3CA and were demonstrated to be insensitive to RNMT
siRNA transfection (figures 1 and 2). As expected, the onco-
genic mutants increased PI3K signalling, as assessed by AKT
phosphorylation (figure 5b,f ). As with ZR-75-1 cells,
expression of oncogenic PIK3CA mutants did not affect
RNMT expression or the efficacy of RNMT siRNA
(figure 5c,g). However, in both cell lines investigated, trans-
fection of two independent RNMT siRNAs caused a
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Figure 6. Expression of PI3K p110a E545K in isogenic human mammary epithelial cells increases dependency on RNMT. (a) Isogenic human mammary epithelial
cells with WT or E545K activating mutation in the PIK3CA gene were transfected with two independent RNMT siRNAs or non-targeting control siRNA for 72 h.
Western blot analysis was performed. (b) Cell number was determined relative to cells transfected with control siRNA. Statistical significance was assessed
using ANOVA followed by Tukey’s multiple comparison tests. *p  0.05; **p  0.01; ***p  0.001. (c) Cancer cell lines HCC38, HCC1569, NCI-H460 and
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number was determined relative to cells transfected with control siRNA. Statistical significance was assessed using ANOVA followed by Dunnett’s multiple comparison
tests, as above. Cells expressing oncogenic PIK3CA mutants are indicated with a red asterisk.
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11significant decrease in cell number in cells expressing
p110a C420R, E545K or H1047R (figure 5d,h; electronic
supplementary material, figure S6a,b).
To extend these findings, similar experiments were per-
formed using isogenic human mammary epithelial cells in
which an endogenous copy of the PIK3CA gene was replaced
by either PIK3CA E545K or WT control. The benefit of these
cell lines is that the PIK3CA mutant is expressed at endogen-
ous levels in an untransformed mammary epithelial cell line.
RNMT expression was reduced by transfection of two inde-
pendent siRNAs resulting in a similar level of knockdown
(figure 6a). Following RNMT reduction, there was a signifi-
cant reduction in p110a E545K-expressing cells but not in
p110a WT-expressing cells (figure 6b).
To extend the finding that oncogenic PIK3CA mutants sen-
sitize cells to a reduction in RNMT, RNMT knockdown was
performed in three more breast cancer cell lines (HCC38,
HCC1569 and HCC1500) and one lung carcinoma cell line
(NCI-H460). The two cell lines with WT PIK3CA (HCC38
and HCC1569) were insensitive to a reduction in RNMT,
whereas the two cell lines with mutations in PIK3CA (NCI-
H460 and HCC1500) exhibited reduced proliferation in
response to RNMT siRNA transfection (figure 6c,d). This isconsistent with cancer cells harbouring oncogenic PIK3CA
mutations exhibiting enhanced dependency on RNMT.3.4. Inhibition of PI3K signalling reduces RNMT
dependency
To further investigate the hypothesis that oncogenic PI3K
p110a signalling increases dependency on RNMT, we used
inhibitors of PI3Ka activity. Phospho-AKT 473 served as a
readout of PI3K inhibitor target engagement (figure 7a,c).
GDC-0941 is a pan PI3K inhibitor which inhibits p110 a, b,
d and g [37] (figure 7a). As expected, reducing RNMT
expression in vehicle-treated T47D and MCF-7 cells signifi-
cantly reduced cell proliferation (figure 7b). However,
incubation with a sub-lethal dose of GDC-0941 suppressed
this proliferative defect. BYL719 selectively inhibits p110a
[37] (figure 7c). As expected, in vehicle-treated T47D and
JIMT cells reducing RNMT expression resulted in reduced
proliferation (figure 7d). However, incubation with a sub-
lethal dose of BYL719 suppressed this proliferative defect.
Therefore, suppression of PI3K p110a activity desensitizes
these cell lines to RNMT inhibition. Collectively, these results
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12demonstrate that PI3K p110a signalling contributes to RNMT
dependency in breast cancer cell lines expressing oncogenic
PIK3CA mutants.4. Discussion
Breast cancer is the most prevalent cancer in women world-
wide, causing over 500 000 deaths annually [35,38].
Although the development of hormone and HER2-targeted
therapies has greatly improved the prognosis of patients
with luminal A/B and HER2 breast cancer, respectively, the
emergence of resistance remains a major problem, limiting
the effectiveness of drug treatment. Moreover, currently,
there are limited treatment options for triple negative breast
cancer, which represent 10–20% of breast cancer cases
[39–41]. The PI3K–AKT–mTOR pathway is a growth and
survival pathway that is frequently deregulated in breast
cancer due to genetic alterations in the pathway, including
activating mutations in the oncogene PIK3CA and deletion
of the tumour suppressor PTEN. Consequently, several inhibi-
tors of this pathway are currently in clinical development for
the treatment of breast cancer [42,43].
Among new targets being explored for the treatment of
cancer are those that target the basic mechanisms of gene
expression [1,2]. Deregulation of common oncogenes (e.g.c-Myc, PIK3CA, Ras and Raf) and loss of common tumour
suppressors (e.g. p53, PTEN and SWI/SNF) are associated
with deregulated or enhanced gene expression. Since the for-
mation of the mRNA cap is a key step in gene expression, we
considered the mRNA cap methyltransferase, RNMT, which
completes the basic functional mRNA cap, as a therapeutic
target. Specifically, we were interested in identifying onco-
genes or tumour suppressors, which sensitize cells to
RNMT inhibition. The aim was to determine which breast
cancer subtypes or gene signatures may be responsive to
therapies targeting RNMT.
To address whether different breast cancer cell lines exhi-
bit differential sensitivity to inhibition of RNMT, we reduced
RNMT expression in a panel of breast cancer cell lines and
non-transformed cells by transfection of RNMT siRNA
(specific inhibitors of RNMT are not currently available).
Using this technique, we reduced cellular cap methyltransfer-
ase activity by 50–60% across the cell panel (figure 3d ). We
observed that a subset of breast cancer cell lines exhibits
enhanced sensitivity to inhibition of RNMT, compared with
a non-transformed control cell line (figures 1 and 6). This
differential dependency on RNMT did not correlate with
RNMT expression level or activity, both in log-phase cells
and following RNMT siRNA transfection (figures 1 and 3).
However, oncogenic mutations in the gene PIK3CA, which
encodes the p110a catalytic subunit of PI3K, were found in
royalsocietypublishing.org/journal/rsob
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13five out of six cancer cell lines exhibiting enhanced sensitivity
to RNMT inhibition (figures 1 and 6, and table 1). Of note,
breast cancer cell lines with PTEN loss (CAMA-1, BT-549
and ZR-75-1) were not sensitive to RNMT inhibition,
suggesting that PIK3CA mutations, rather than PTEN loss,
promotes RNMT dependency in breast cancer. This obser-
vation is consistent with an emerging body of data,
suggesting that genetic alterations in different parts of the
PI3K pathway have distinct biological effects [44–46].
HCC1806 cells do not have a PIK3CA mutation but do
have an LKB1 deletion. As LKB1 indirectly suppresses
mTOR signalling via AMPK, LKB1 deletion increases
mTOR signalling, as does mutant PIK3CA via AKT signal-
ling. Although the mTOR signalling pathway is unlikely to
provide a complete explanation as to why HCC1806 cells
are sensitive to RNMT inhibition, the LKB1 deletion may
contribute to the phenotype.
Strengthening the link between PIK3CA mutations and
RNMT inhibition, breast cancer cell lines and mammary epi-
thelial cells, which were insensitive to RNMT siRNA
transfection, could be rendered sensitive by the expression of
PIK3CA oncogenic mutants (figures 4 and 5). Conversely,
breast cell lines with endogenous oncogenic PIK3CAmutations
were desensitized to RNMT repression by the use of PI3Ka
inhibitors (figure 7), suggesting that oncogenic PIK3CA
mutations promote RNMT dependence through increased
PI3Ka signalling. Collectively, these data indicate that breast
cells harbouring oncogenic PIK3CA mutations have enhanced
dependence on RNMT (mRNA cap methylation) for prolifer-
ation and survival, making RNMT a promising therapeutic
target in PIK3CA mutant breast cancer. Since approximately
35% of all breast cancers contain mutations in PIK3CA, these
findings could have a significant impact.4.1. Why do oncogenic PIK3CA mutations increase
dependency on RNMT?
The mRNA cap protects transcripts from degradation and
recruits protein complexes involved in RNA processing and
translation [47,48]. RNMT also has a major role in enhancing
the transcription of the most highly expressed genes [11]. In
previous studies in which levels of RNMT or its activator
RAM were altered, genes responded differentially at the
mRNA level and translation rate [11,14,19,49,50]. This results
in cellular proteins and signalling pathways being differen-
tially dependent on RNMT for expression. Why are genes
differentially dependent on RNMT? Some transcripts may
be dependent on high concentrations of RNMT to be methyl-
ated correctly. Certain guanosine-capped transcripts may
have limited access to RNMT, because of the chromatin
context, the speed of transcription or RNA secondary struc-
ture. Alternatively, some transcripts may not require their
mRNA cap to be methylated on the cap guanosine, such as
by using IRES (internal ribosome entry site)-dependent trans-
lation initiation. Although RNMT-catalysed methylation of
the mRNA cap guanosine increases affinity for cap-binding
complexes, it is not absolutely required. Some transcripts
may be largely independent of the cap guanosine methyl-
ation for translation initiation. In experiments performed
here, when cellular RNMT activity was reduced by approxi-
mately 50%, the global translation rate (approximated by
amino acid incorporation into proteins) was reduced byonly 5–10% in most cell lines investigated, indicating that
RNMT is present in excess for the expression of most
genes (figure 3f ).
The mechanism by which oncogenic PIK3CA increases
dependency on RNMT remains an open question. Oncogenic
PIK3CA mutants (and downstream activation of mTORC1-
driven cap-dependent translation) may alter the expression
of proteins which render cells sensitive to RNMT inhibition.
Alternatively, RNMT inhibition may affect protein expression
similarly in all breast cancer cell lines, regardless of PIK3CA
status; cells expressing PIK3CA may have increased depen-
dency on a subset of RNMT-dependent proteins as a
mechanism of oncogene addiction. We investigated whether
the expression or phosphorylation of direct or indirect AKT
substrates, which are involved in mRNA translation, were
differentially expressed in IMECs and the breast cancer cell
lines (electronic supplementary material, figure S7). The
expression and phosphorylation level of AKT, eIF4E BP-1
and P70-S6 kinase did not correlate with sensitivity to
RNMT suppression. We also investigated whether expression
of the p85 and p110 subunits of PI3K were supressed in
response to RNMT siRNA transfection, in MCF7 and
HCC1806 (sensitive to RNMT siRNA transfection), and
MDA-MB-231 and ZR-75-1 (insensitive to RNMT siRNA
transfection). Expression of p85 and p110 was not robustly
up or downregulated following 48 and 72 h RNMT siRNA
transfection (electronic supplementary material, figure S8a).
This experiment was also repeated with three independent
RNMT siRNAs with similar results (not shown). This
suggests that PIK3CA oncogenic mutations increase depen-
dency on RNMT independently of increasing translation of
p85 and p110.
In HeLa cells and other lines, repression of capping
enzymes results in repression of c-Myc expression and
RNA pol II phosphorylation [11,15]. c-Myc is induced by
mitogenic signalling (including via the PI3K pathway) to
promote cell proliferation, including increasing RNA pol
II phosphorylation, which reflects global transcription
levels. We therefore investigated whether, in the cell lines
sensitive to RNMT siRNA transfection, c-Myc and/or
RNA pol II phosphorylation is repressed when RNMT
expression is reduced. In MCF7, HCC-1806, JIMT-1 and
T47D cells, c-Myc expression and RNA pol II phosphoryl-
ation were not consistently repressed in response to RNMT
siRNA transfection (electronic supplementary material,
figure S8b). Deep proteomic analyses of a large panel of
breast carcinoma cell lines will be useful in identifying
the full spectrum of RNMT-dependent proteins in
PIK3CA-mutant breast cancer.
In this study we provide evidence to suggest RNMT
should be explored as a therapeutic target in breast cancers
harbouring PI3K p110a mutations. The development of
specific tool compounds, which inhibit RNMT function and
the elucidation of the function of RNMT in vivo, will be
important next steps in these investigations.
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